INCY vs. ONC: Incyte vs. BeOne Medicines Stock Comparison
How do Incyte (INCY) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Incyte (INCY) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Incyte (INCY) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | INCY | ONC |
|---|---|---|
| Name | Incyte Corp. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 24.39 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | November 4, 1993 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INCY | ONC |
|---|---|---|
| Total Return (1Y) | 14.06% | 30.59% |
| Total Return (3Y, Annualized) | 32.03% | 30.15% |
| Total Return (5Y, Annualized) | 12.69% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INCY | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 33.19% | 35.90% |
| Beta (5Y) | 0.78 | 0.59 |
| Max Drawdown (5Y) | -40.50% | -68.89% |
| Avg. Volume (3M) | 1.58M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INCY | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 0.29 | 0.73 |
| Sortino Ratio (1Y) | 0.46 | 1.15 |
Profitability
ROE (TTM)
Both Incyte (INCY) at 7.84% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Incyte (INCY) at 6.71% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Incyte (INCY) at 33.72% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INCY | ONC |
|---|---|---|
| ROE (TTM) | 7.84% | 18.40% |
| ROA (TTM) | 17.78% | 8.42% |
| Net Margin (TTM) | 6.71% | 13.86% |
| Operating Margin (TTM) | 33.72% | 22.15% |
| Gross Margin (TTM) | 56.02% | 89.39% |
Growth
Revenue Growth
Both Incyte (INCY) at 21.22% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Incyte (INCY) reports EPS growth of 4,173.33%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | INCY | ONC |
|---|---|---|
| Revenue Growth (YoY) | 21.22% | 40.23% |
| Revenue Growth (3Y CAGR) | 14.84% | 55.69% |
| EPS Growth (YoY) | 4,173.33% | -- |
| EPS Growth (3Y CAGR) | 61.56% | -- |
Financial Strength
Current Ratio (MRQ)
Both Incyte (INCY) at 3.84 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while BeOne Medicines (ONC) at 0.35 runs a more typical debt-to-equity mix.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INCY | ONC |
|---|---|---|
| Current Ratio (MRQ) | 3.84 | 3.55 |
| Debt / Equity (MRQ) | 0.01 | 0.35 |
| Net Debt / EBITDA | -1.88 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Incyte (INCY) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Incyte (INCY) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INCY | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Incyte (INCY) at 61.05 and BeOne Medicines (ONC) at 52.17 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Incyte (INCY) at 4.06 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INCY | ONC |
|---|---|---|
| P/E Ratio (TTM) | 61.05 | 52.17 |
| P/S Ratio (TTM) | 4.06 | 7.04 |
| P/B Ratio (MRQ) | 4.33 | 7.98 |
| Free Cash Flow Yield (TTM) | 5.28% | 2.21% |